Tango Therapeutics Stock Soars 36.3% on Erasca Collaboration for MTAP-Deleted Cancer Study
Tango Therapeutics shares surged 36.3% to a record high after securing a non-exclusive clinical trial collaboration and supply agreement with Erasca. The Phase I/II study will combine Erasca’s ERAS-0015 with Tango’s vopimetostat in MTAP-deleted pancreatic cancer and RAS-mutant NSCLC patients.
1. Deal Announcement and Stock Surge
Shares of Tango Therapeutics jumped 36.3% to a record high after the company inked a non-exclusive clinical trial collaboration and supply agreement with Erasca. The deal propelled the biotech’s valuation as investors reacted to the potential of the combined therapy.
2. Collaboration Study Details
Under the agreement, Erasca will provide its pan-RAS molecular glue ERAS-0015 at no cost, while Tango sponsors a Phase I/II study. The trial will evaluate ERAS-0015 alongside Tango’s MTAP-deleted selective PRMT5 inhibitor, vopimetostat (TNG462), in patients with MTAP-deleted pancreatic cancer and RAS-mutant NSCLC.
3. Strategic Rights and Therapeutic Rationale
Both companies will retain commercial rights to their respective therapies under the non-exclusive deal. By targeting co-occurring RAS mutations and PRMT5 dependency in MTAP-deleted tumors, the combination aims to enhance tumor suppression and improve response durability.
4. Stock Performance and Pipeline Context
Tango shares have climbed 147.1% over the past six months versus 19.7% industry growth, reflecting investor enthusiasm for its clinical pipeline. Upcoming milestones include pivotal vopimetostat monotherapy trials in second-line pancreatic cancer and combination studies with Revolution Medicines.